What is Amoxiplus ratiopharm forte?
Amoxicillin (Amoxiplus ratiopharm forte) is an antibiotic in a group of drugs called penicillins. Amoxicillin (Amoxiplus ratiopharm forte) fights bacteria in the body.
Clavulanate potassium is a form of Clavulanic Acid (Amoxiplus ratiopharm forte), which is similar to penicillin. Clavulanate potassium fights bacteria that is often resistant to penicillins and other antibiotics.
The combination of Amoxicillin (Amoxiplus ratiopharm forte) and clavulanate potassium is used to treat many different infections caused by bacteria, such as sinusitis, pneumonia, ear infections, bronchitis, urinary tract infections, and infections of the skin.
Amoxicillin (Amoxiplus ratiopharm forte) and clavulanate potassium may also be used for purposes not listed in this medication guide.
Amoxiplus ratiopharm forte indications
Amoxiplus ratiopharm forte-600 is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs ≤ 2 mcg/mL), H. influenzae (including β-lactamase–producing strains), or M. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors:
- antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following:
- age ≤ 2 years
- daycare attendance
NOTE: Acute otitis media due to S. pneumoniae alone can be treated with Amoxicillin (Amoxiplus ratiopharm forte). Amoxiplus ratiopharm forte-600 is not indicated for the treatment of acute otitis media due to S. pneumoniae with penicillin MIC ≥ 4 mcg/mL.
Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both S. pneumoniae (penicillin MIC ≤ 2 mcg/mL) and the β-lactamase–producing organisms listed above.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxiplus ratiopharm forte-600 and other antibacterial drugs, Amoxiplus ratiopharm forte-600 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Amoxiplus ratiopharm forte description
Each film-coated tablet contains Amoxicillin (Amoxiplus ratiopharm forte) trihydrate equivalent to Amoxicillin (Amoxiplus ratiopharm forte) 500 mg, and potassium clavulanate equivalent to Clavulanic Acid (Amoxiplus ratiopharm forte) 125 mg, respectively.
Each vial contains Amoxicillin (Amoxiplus ratiopharm forte) sodium equivalent to Amoxicillin (Amoxiplus ratiopharm forte) 1000 mg and clavulanate potassium equivalent to Clavulanic Acid (Amoxiplus ratiopharm forte) 200 mg, respectively.
Amoxiplus ratiopharm forte tablets also contains the following excipients: Microcrystalline cellulose, sodium starch glycolate, anhydrous colloidal silica, povidone (K30), eudragit E 100, isopropyl alcohol, magnesium stearate, white opadryl 03B58965, PEG400, methylene chloride.
Amoxiplus ratiopharm forte is an antibacterial combination consisting of the semi-synthetic antibiotic Amoxicillin (Amoxiplus ratiopharm forte) and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of Clavulanic Acid (Amoxiplus ratiopharm forte)). Amoxicillin (Amoxiplus ratiopharm forte) is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. Its molecular formula is C16H19N305S3H20 and the molecular weight is 419.46. Chemically, Amoxicillin (Amoxiplus ratiopharm forte) is (2S, 5R, 6R)-6-[(R)-(-)-2-Amino-2-(p-hydroxyphenyl) acetamido]-3, 3-dimethyl-7-oxo-4-1-azabicyclo[3.2.1] heptane-2-carboxylic acid trihydrate.
Amoxicillin (Amoxiplus ratiopharm forte): Clavulanic Acid (Amoxiplus ratiopharm forte) is produced by the fermentation of Streptomyces clavuligerus. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic Acid (Amoxiplus ratiopharm forte) is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C8H8KN05 and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (Z)-(2R, 5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate.
Amoxiplus ratiopharm forte dosage
Tablet: Tablets should be taken immediately before a meal.
General Information: For infections caused by Amoxicillin (Amoxiplus ratiopharm forte)-sensitive organisms, the dosage is that approved for Amoxicillin (Amoxiplus ratiopharm forte) as the Clavulanic Acid (Amoxiplus ratiopharm forte) component does not contribute to the therapeutic effect.
Adults: 1 or 2 Amoxiplus ratiopharm forte 375 mg tab 8 hourly or 1 Amoxiplus ratiopharm forte 625 mg tab 8 hourly for more severe infections and infections of the respiratory tract.
For Amoxicillin (Amoxiplus ratiopharm forte)-resistant organisms, the dosage of Amoxiplus ratiopharm forte tablets are as follows:
Since both Amoxiplus ratiopharm forte 375 mg and 625 mg contain the same amount of Clavulanic Acid (Amoxiplus ratiopharm forte) (125 mg, as the potassium salt), 2 Amoxiplus ratiopharm forte 375 mg are not equivalent to 1 Amoxiplus ratiopharm forte 625 mg. Therefore, 2 Amoxiplus ratiopharm forte 375 mg should not be substituted for 1 Amoxiplus ratiopharm forte 625 mg for treatment of more severe infections.
Renal Failure: Both Amoxicillin (Amoxiplus ratiopharm forte) and Clavulanic Acid (Amoxiplus ratiopharm forte) are excreted by the kidneys and the serum t½ of each increases in patients with renal failure. Therefore, the dose may need to be reduced or the interval extended. The following schedule in the dosage is proposed:
Haemodialysis decreases serum concentrations of both Amoxicillin (Amoxiplus ratiopharm forte) and Clavulanic Acid (Amoxiplus ratiopharm forte) and an additional dose should be administered at the end of dialysis.
Oral Suspension:
Suspensions should be taken immediately before a meal.Reconstitution: For reconstitution to 30 mL, add water till the mark, invert the bottle and shake well until all the powder is dispersed.
Children: 25-50 mg/kg/day of the 4 parts Amoxicillin (Amoxiplus ratiopharm forte), 1 part Clavulanic Acid (Amoxiplus ratiopharm forte) preparations (which corresponds to a daily dosage of the equivalent of Amoxicillin (Amoxiplus ratiopharm forte) 20-40 mg/kg and Clavulanic Acid (Amoxiplus ratiopharm forte) 5-10 mg/kg) to be taken in divided doses every 8 hrs at the start of a meal.
Dosage Guide:
To correspond to a dosage of 25-50 mg/kg/day.
To correspond to a dosage of 50 mg/kg/day.
IV/IM: Amoxiplus ratiopharm forte may be administered by the IV routes.
Amoxiplus ratiopharm forte is administered by IM or slow IV injection in doses of 500 mg every 8 hrs.
Severe Infections: 1 g every 6 hrs by slow IV injection over 3-4 min or by infusion over 30-60 min.
Children ≤10 years: 50-100 mg/kg body weight daily by injection in divided doses.
Amoxiplus ratiopharm forte interactions
See also:
What other drugs will affect Amoxiplus ratiopharm forte?
Probenecid decreases the renal excretion of Amoxicillin (Amoxiplus ratiopharm forte). Concurrent use with Amoxiplus ratiopharm forte may result in increased and prolonged blood levels of Amoxicillin (Amoxiplus ratiopharm forte).
The concurrent administration of allopurinol and ampicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. But it is not known whether this potentiation of ampicillin rash is due to allopurinol or the hyperuricemia present in these patients.
Amoxiplus ratiopharm forte should not be co-administrated with disulfiram.
Prolongation of bleeding time and prothrombin time have been reported in some patients receiving Amoxiplus ratiopharm forte. Thus, Amoxiplus ratiopharm forte should be used with care in patients on anticoagulation therapy.
Amoxiplus ratiopharm forte may reduce the effect of oral contraceptives and the caution should be given to patients.
Laboratory Test Interactions: Amoxiplus ratiopharm forte results in high urine concentration. High urine concentration of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using Clinitest, Benedict or Fehling's solution.
Amoxiplus ratiopharm forte side effects
See also:
What are the possible side effects of Amoxiplus ratiopharm forte?
The most frequently reported adverse effects were diarrhoea, nausea, vomiting, abdominal pain, skin rashes, urticaria and erythema multiforme, vaginitis, abnormal taste, headache, dizziness, tiredness and hot flushes. The incidence and severity of adverse effects, particularly nausea and diarrhoea, increased with the higher recommended dose and can be minimised by administering the agent at the start of a meal. In addition, as these symptoms are especially related to the potassium clavulanate component, where these GI symptoms occur and a higher concentration of Amoxicillin (Amoxiplus ratiopharm forte) is required, consideration should be given to administering the additional Amoxicillin (Amoxiplus ratiopharm forte) separately.
Hepatitis and cholestatic jaundice have been reported with the combination of Amoxicillin (Amoxiplus ratiopharm forte) and Clavulanic Acid (Amoxiplus ratiopharm forte); the Clavulanic Acid (Amoxiplus ratiopharm forte) component has been implicated. The events associated with Amoxiplus ratiopharm forte may be severe and occur predominantly in adult or elderly patients. Signs and symptoms usually occur during or shortly after treatment, but in some cases may not become apparent until several weeks after treatment has ceased. The hepatic events are usually reversible. However, in extremely rare circumstances, death has been reported. These have almost always been cases associated with serious underlying disease or concomitant medication.
A moderate rise in aspartate transaminase and/or alanine transaminase has been noted in patients treated with Amoxiplus ratiopharm forte, the significance of these findings is unknown.
The following adverse reactions have been reported for ampicillin class antibiotics and may occur with Amoxiplus ratiopharm forte.
Gastrointestinal: Gastritis, stomatitis, glossitis, black hairy tongue, enterocolitis and pseudomembranous colitis. If GI reactions are evident, they may be reduced by taking Amoxiplus ratiopharm forte at the start of a meal.
Amoxicillin (Amoxiplus ratiopharm forte) causes hypersensitivity reactions similar to those induced by penicillin G and ampicillin, including rashes and fever. The incidence of these reaction is probably no higher than with other penicillins. Sensitivity reactions are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever or uticaria. Hypersensitivity reactions include skin rashes, urticaria, erythema multiforme, rare cases of Stevens-Johnson syndrome and less frequently exfoliative dermatitis and toxic epidermal necrolysis have been reported. Whenever such reactions occur, Amoxiplus ratiopharm forte should be discontinued. Serious and occasional fatal hypersensitivity (anaphylactic) reactions and angioneurotic oedema can occur with oral penicillin.
Haematopoietic and Lymphatic: Anaemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leucopenia and agranulocytosis have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. A slight thrombocytosis was noted in patients treated with Amoxiplus ratiopharm forte. Prolongation of bleeding time and prothrombin time have also been reported less frequently.
Amoxicillin (Amoxiplus ratiopharm forte) alone or in combination with Clavulanic Acid (Amoxiplus ratiopharm forte) has been associated with acute hepatic dysfunction. The incidence rate (95% confidence intervals) were 1.7 (1.1-2.7) (Amoxicillin (Amoxiplus ratiopharm forte)-Clavulanic Acid (Amoxiplus ratiopharm forte)) and 0.3 (0.2-0.5)/10,000 prescriptions (Amoxicillin (Amoxiplus ratiopharm forte) alone). Risks were increased in patients receiving >1 course and in older recipients.
Central Nervous System: Reversible hyperactivity, agitation, anxiety, insomnia, confusion, behavioural changes and/or dizziness have also been reported. Depression, seizures or hallucinations.
Amoxiplus ratiopharm forte contraindications
Hypersensitivity to the Amoxicillin (Amoxiplus ratiopharm forte)/clavulanate potassium to any of the penicillins or to any of the excipients of Amoxiplus ratiopharm forte.
History of a severe immediate hypersensitivity reaction (eg, anaphylaxis) to another β-lactam agent (eg, a cephalosporin, carbapenem or monobactam).
History of cholestatic jaundice/hepatic dysfunction due to Amoxiplus ratiopharm forte.
Active ingredient matches for Amoxiplus ratiopharm forte:
Amoxicillin/Clavulanic Acid in Austria.
List of Amoxiplus ratiopharm forte substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Amoxiplus ratiopharm forte 312,5 mg/5 ml (Austria) | |
| Amoxistad plus (Austria) | |
| Amoxistad plus 875 mg/125 mg (Austria) | |
| Amoxitenk (Argentina) | |
| Amoxitenk Plus (Argentina) | |
| Amoxitenk Plus Pediátrica (Argentina) | |
| AMOXRAG (India) | |
| 1's (Auriga) | $ 1.45 |
| 6's (Auriga) | $ 2.17 |
| Amoxrag Amoxicillin 1 g, clavulanicacid 0.2 g. POWD / 1 (Auriga) | $ 1.45 |
| Amoxrag Amoxicillin 250 mg, clavulanicacid 125 mg. TAB / 6 (Auriga) | $ 1.59 |
| Amoxrag Amoxicillin 500 mg, clavulanicacid 125 mg. TAB / 6 (Auriga) | $ 2.17 |
| AMOXRAG tab 6's (Auriga) | $ 2.17 |
| Amoxrag Amoxicillin 1 g, clavulanicacid 0.2 g. POWD / 1 (Auriga) | $ 1.45 |
| Amoxrag Amoxicillin 250 mg, clavulanicacid 125 mg. TAB / 6 (Auriga) | $ 1.59 |
| Amoxrag Amoxicillin 500 mg, clavulanicacid 125 mg. TAB / 6 (Auriga) | $ 2.17 |
| Amoxrag Syr (India) | |
| Amoxrag Syr Amoxicillin 200 mg, clavulanicacid 28.5 mg/5 mL. DRY-SYR / 30ml (Auriga) | $ 0.84 |
| AMOXRAG SYR dry syr 30ml (Auriga) | $ 0.84 |
| Amoxtacim (South Korea) | |
| Amoxtal-CA (India) | |
| Amoxtal-CA Amoxicillin 500 mg, Clavulanicacid 125 mg. TAB / 6 (Talson) | $ 3.60 |
| 6's (Talson) | $ 3.60 |
| AMOXTAL-CA tab 6's (Talson) | $ 3.60 |
| Amoxy + Clav Potas Com | |
| Amoxy Clav | |
| AMOXY PLUS | |
| AMOXY PLUS 200 MG/28.5 MG DRY SYRUP 1 bottle / 30 ML dry syrup each (Symbiosis Lab) | $ 0.71 |
| AMOXY PLUS 500 MG/125 MG TABLET 1 strip / 10 tablets each (Symbiosis Lab) | $ 0.82 |
| Amoxy Plus 500 mg/125 mg Tablet (Symbiosis Lab) | $ 0.08 |
| AMOXY(SYMBIOSIS) | |
| AMOXY PLUS CV 500 MG/125 MG TABLET 1 strip / 6 tablets each (Symbiosis Lab) | $ 1.77 |
| AMOXYCILLIN 250MG+POTASSIUM CLAVULANATE 125MG | |
| AMOXYCILLIN 250MG+POTASSIUM CLAVULANATE 125MG TABLET 1 strip / 6 tablets each (Jan Aushadhi) | $ 0.36 |
| Amoxycillin; Clavulanic Acid | |
| Amoxyclav (Australia, Georgia) | |
| Injectable; Injection; Amoxicillin Sodium 1000 mg; Clavulanic Acid / Clavulanate Potassium 200 mg (Abbott) | |
| Amoxyclav Amoxicillin 1 g, clavulanatepotassium 0.2 g. POWD / 1 (Abbott) | $ 2.16 |
| AMOXYCLAV 1000 MG/200 MG INJECTION 1 vial / 1 injection each (Abbott) | $ 0.68 |
| AMOXYCLAV 500 MG/125 MG TABLET 1 strip / 6 tablets each (Abbott) | $ 1.23 |
| Amoxyclav 1000 mg/200 mg Injection (Abbott) | $ 0.72 |
| Amoxyclav 250mg/125mg Tablet (Abbott) | $ 0.10 |
| Amoxyclav 500 mg/125 mg Tablet (Abbott) | $ 0.21 |
| Amoxyclav 200 (Australia) | |
| Amoxyclav 250 (Australia) | |
| Amoxyclav 50 (Australia) | |
| Amoxyclav 500 (Australia) | |
| Amoxyclav AN (Australia) | |
| Amoxyclav Generichealth (Australia) | |
See 7042 substitutes for Amoxiplus ratiopharm forte | |
References
- DailyMed. "AMOXICILLIN; CLAVULANATE POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "CLAVULANIC ACID". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "amoxicillin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Amoxiplus ratiopharm forte are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Amoxiplus ratiopharm forte. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
